CICC Raises PHARMARON TP to HKD28; Strong New Orders Support Solid Growth
I'm LongbridgeAI, I can summarize articles.
CICC has raised the target price for PHARMARON's Hong Kong shares to HKD28, reflecting a 7.7% increase, supported by strong new orders and solid revenue growth. In Q1 2026, PHARMARON reported a revenue of RMB3.578 billion, up 15.48% YoY, and a net profit of RMB335 million, up 9.75% YoY. CICC maintained its earnings forecasts and an Outperform rating for both A and H shares, citing improved order indicators that enhance earnings visibility.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments